NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Quanterix Corporation Common Stock (QTRX) Stock Analysis

Quanterix Corporation Common Stock (QTRX) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

QTRX

$2.69

+$0.11 (+4.26%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare QTRX with… →

QTRX Key Statistics

As of Sep 4, 2026
Trading
Open
$2.58
Previous Close
$2.58
Day's Range
2.54–2.70
52-Week Range
2.15–8.77
Volume
274.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.04
Valuation
Market Cap
$127.22M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.83
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.72
Financials (FY)
Revenue (FY)
$138.65M+2.38%
Net Income (FY)
−$107.15M
Profit marginThe share of revenue left as profit after all costs and taxes.
−80.25%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
47.29M
1-Year Return
−37.73%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
840.64K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

QTRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−57.70%
2025−40.17%
2024−61.12%
2023+97.40%
2022−67.33%
2021−8.82%
2020+96.78%
2019+29.06%
2018−14.72%
2017 (partial year)+22.90%

As of September 4, 2026.

QTRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$138.65M−$107.15M−77.3%
2024$135.44M−$38.53M−28.4%
2023$121.14M−$28.35M−23.4%
2022$104.95M−$99.57M−94.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$138.65M$64.72M−$109.82M−$107.15M−77.3%
2024$135.44M$81.12M−$52.62M−$38.53M−28.4%
2023$121.14M$73.00M−$44.66M−$28.35M−23.4%
2022$104.95M$44.79M−$74.71M−$99.57M−94.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

QTRX Valuation vs Medical Devices Median

Median of 151 stocks
MetricQTRXMedical Devices medianvs median
P/S ratio0.832.980.3x the median
Profit margin−80.25%−1.69%78.6 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Quanterix Corporation Common Stock (QTRX) is capitalised at $127.22M on the latest close. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 450.

Over the past 52 weeks the price has ranged from $2.15 to $8.77. QTRX last closed at $2.69 on September 4, 2026. That is +$0.11 (+4.26%) against the previous close. The latest close sits 25.12% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $138.65M. Against the prior fiscal year total of $135.44M, that is a change of +2.38%. The same year closed with a net loss of $107.15M. Profit margin runs at −80.25%. That is 78.6 percentage points below the Medical Devices median of −1.69%. Trailing earnings per share are −2.72.

Across the 4 fiscal years on file, revenue moves from $104.95M in 2022 to $138.65M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 0.83 times revenue. On price-to-sales that is 0.3 times the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The trailing one-year price return is −37.73%. Across 5 years the annualized return works out at −44.61%. The reported beta is 1.04. Daily returns over the trailing 8 years annualize to a volatility of 79.9%.

Growth & Income

The record shows no dividend for QTRX.

So far in 2026 the price is −57.70%. Across the complete calendar years on file, 2023 returned +97.40% and 2022 returned −67.33%. Of the 8 complete calendar years on file, 3 finished higher.

Peer Comparison

Quanterix Corporation Common Stock (QTRX) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Quanterix Corporation Common Stock QTRX $127.22M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Quanterix Corporation Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Quanterix Corporation Common Stock

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Visit website →